Alitretinoin as a potential advance in the management of severe chronic hand eczema

Archives of Dermatology

Volumn 145, Issue 3, 2009, Pages 314-315

  Ingram, John R ^a   Batchelor, Jonathan M ^b   Williams, Hywel C ^c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; CORTICOSTEROID;

CANADA; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; HAND ECZEMA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOTE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 62649088909     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.608     Document Type: Note

References (4)

1. Van Coevorden AM, Coenraads PJ, Svensson A, et al. Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. Br J Dermatol. 2004; 151(2):446-451.
2. Riuzicka T, Larsen FG, Galewiez D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004;140(12):1453-1459.
3. Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of a retinoid for the treatment of severe chronic hand dermatitis. http://clinicaltrials.gov/ ct2/show/record/NCT00124475. Accessed August 14, 2008.
4. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004:291 (20):2457-2465.